09Oct
Caremark Round II: Beware Red Flags in Drug Development
On October 1, 2019, the Delaware Court of Chancery applied the Delaware Supreme Court’s recent decision on Caremark board oversight claims in the context of operating in a highly regulated industry to allow derivative claims to proceed against the...
By:
Goodwin
Related
Since the advent of computers there have always been fear of job losses, but new jobs have been crea...
Read More >
Amidst the COVID-19 pandemic, total buyout volume in the first half of 2020 dropped 23% annually, wh...
Read More >
Recently, the comment period ended for the Department of Labor’s Notice of Proposed Rulemaking seek...
Read More >
Your company has just made its largest acquisition ever and your CEO says they want you to have a co...
Read More >
What is CFIUS? The Committee on Foreign Investment in the United States (CFIUS) is an interagency co...
Read More >
As trade with our North American neighbors continues to evolve and grow, we’re taking a closer look...
Read More >